-0.01 | -0.49%
| Price and Volume | |
|---|---|
| Recent Price | 2.05 |
| 52 Week High | 3.47 |
| 52 Week Low | 1.75 |
| Avg. Daily Vol. (Mil) | 0.34 |
| Beta (3 year) | 0.80 |
| Share Related Items | |
| Mkt Cap (Mil) | 79.45 |
| Shares Out (Mil) | 38.76 |
| Float (Mil) | 38.55 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.60 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 7.22K |
| Price/Book | 0.00 |
| Price/Cash Flow | -3.30 |
| Per Share Data | |
| Earnings | -0.63 |
| Sales | 0.00 |
| Book Value | 0.00 |
| Cash Flow | -0.61 |
| Business Summary | |
|---|---|
| Aastrom Biosciences, Inc. is regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology. | |
| General Information | |
| 24 Frank Lloyd Wright Drive
P.O. Box 376 Ann Arbor, MI 48106 |
|
| www.aastrom.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 71 | |
| CEO: Timothy M. Mayleben | |
| Short Interest | |
| Current Month (Mil) | 2.72 |
| Previous Month (Mil) | 2.71 |
| Short Interest Ratio (Days) | 9.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -62.40 |
| Return on Investments | 111.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet